Human antibodies to the 19 kDa C‐terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro

AF EGAN, P BURGHAUS, P DRUILHE… - Parasite …, 1999 - Wiley Online Library
AF EGAN, P BURGHAUS, P DRUILHE, AA HOLDER, EM RILEY
Parasite immunology, 1999Wiley Online Library
The 19 kDa, C‐terminal fragment of the major surface protein of Plasmodium falciparum
(PfMSP119) is a candidate for inclusion in a subunit malaria vaccine. In this study, we show
that PfMSP119‐specific antibodies, affinity purified from malaria‐immune human serum,
can:(i) compete with invasion‐inhibitory monoclonal antibodies for binding to PfMSP119 and
(ii) mediate inhibition of parasite growth in vitro, in the absence of complement and
mononuclear cells, at physiological antibody concentrations (100 μg/ml). Parasites …
The 19 kDa, C‐terminal fragment of the major surface protein of Plasmodium falciparum (PfMSP119) is a candidate for inclusion in a subunit malaria vaccine. In this study, we show that PfMSP119‐specific antibodies, affinity purified from malaria‐immune human serum, can: (i) compete with invasion‐inhibitory monoclonal antibodies for binding to PfMSP119 and (ii) mediate inhibition of parasite growth in vitro, in the absence of complement and mononuclear cells, at physiological antibody concentrations (100 μg/ml). Parasites expressing either the K1 or 3D7 allele of PfMSP119 were equally susceptible to inhibition of merozoite invasion, indicating that the target epitopes of inhibitory antibodies are conserved or cross‐reactive. These studies suggest that vaccines designed to induce antibodies to PfMSP119 may protect against the high levels of malaria parasitaemia which are associated with clinical disease.
Wiley Online Library